In the last trading session, 1.3 million shares of the X4 Pharmaceuticals Inc (NASDAQ:XFOR) were traded, and its beta was 0.48. Most recently the company’s share price was $0.31, and it changed around $0.01 or 0.95% from the last close, which brings the market valuation of the company to $53.37M. XFOR currently trades at a discount to its 52-week high of $1.60, offering almost -416.13% off that amount. The share price’s 52-week low was $0.26, which indicates that the current value has risen by an impressive 16.13% since then. We note from X4 Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.53 million shares, with the 3-month average coming to 3.71 million.
X4 Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended XFOR as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. X4 Pharmaceuticals Inc is expected to report earnings per share of -0.16 for the current quarter.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
Instantly XFOR has showed a green trend with a performance of 0.95% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3386 on recent trading dayincreased the stock’s daily price by 8.45%. The company’s shares are currently down -58.11% year-to-date, but still down -9.64% over the last five days. On the other hand, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is -35.09% down in the 30-day period. We can see from the shorts that 9.48 million shares have been sold at a short interest cover period of 1.59 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 89.67% from its current value. Analyst projections state that XFOR is forecast to be at a low of $3 and a high of $5.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 1.06M in revenue for the current quarter. 3 analysts expect X4 Pharmaceuticals Inc to make 2.39M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 73.95%. X4 Pharmaceuticals Inc earnings are expected to increase by 77.19% in 2025, but the outlook is positive 13.89% per year for the next five years.
XFOR Dividends
X4 Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Nov-12.
X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.27% of X4 Pharmaceuticals Inc shares, and 59.20% of them are in the hands of institutional investors. The stock currently has a share float of 59.96%. X4 Pharmaceuticals Inc stock is held by 114.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 8.4393% of the shares, which is about 16.92 million shares worth $9.81 million.
NEA MANAGEMENT COMPANY, LLC, with 7.4769% or 14.99 million shares worth $8.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
